Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Feb 12, 2023 3:49pm
75 Views
Post# 35282210

RE:RE:Wow

RE:RE:WowI am also sitting on a pile of shares.   I agree this is a big gamble but I am confident that we will see a return on our investment. One way or another I think the dermal Injector will take us eventually to $1.00+ and it is not that far away.  We may even get an update before the AGM at the end of the month.
It will be interesting to see how the next 5 months play out with Shiseido and Replicel.  As we have mentioned before it could go in many different ways. One senario I had not previously thought of is Shiseido waits until the arbitrators judgement is rendered before  some sort of a deal is struck.  They may be holding out just in case they win the arbitration.  Why make a deal when you don't have to. The problem with that for them is if it looks like they will loose it would be cheaper to make a deal before the judgement than after. 
<< Previous
Bullboard Posts
Next >>